http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-074061-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a86ec4321b3682fe1b78890265532da |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-417 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 |
| filingDate | 2009-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_288143d893f12895f2402a9073424f40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85a7171a68600848a9cd52bbb01081f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_106b80e6737c19dbbe97dc3efa297eec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfc30b7014c0f7de82c8fda737654919 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_110a2ed24ebbb3a9d91e21f1aafc9ffa |
| publicationDate | 2010-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-074061-A1 |
| titleOfInvention | S1P LIASA INHIBITORS FOR THE TREATMENT OF CEREBRAL MALARIA AND PHARMACEUTICAL FORMULATION |
| abstract | Claim 1: Use of an S1P lyase inhibitor in the preparation of a medicament for treating, managing and / or preventing cerebral malaria. Claim 4: The use of any one of claims 1-3 wherein the S1P lyase inhibitor is a compound of the formula: 1 or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen, alkyl or aryl; R3 is OR3a, NHC (O) R3a, NHSO2R3a or hydrogen; each R3a is independently hydrogen or alkyl, aryl, alkylaryl, arylalkyl, heteroalkyl, heterocycle, alkylheterocycle or heterocycloalkyl, optionally substituted with halo: R6 is OR6a or OC (O) R6a; R7 is OR7a or OC (O) R7a; R8 is OR8a or OC (O) R8a; R9 is hydrogen, CH2OR9a or CH2OC (O) R9a; and each R6a, R7a, R8a and R9a is, independently, hydrogen or lower alkyl. Claim 7: The use of any one of claims 1-3, wherein the S1P lyase inhibitor is a compound of the formula: 2 or a pharmaceutically acceptable salt thereof, wherein: A is an optionally substituted heterocycle; R5 is OR5a or OC (O) R5a; R6 is OR6a, or OC (O) R6a; R7 is OR7a or OC (O) R7a; R8 is hydrogen, CH2OR8a or CH2OC (O) R8a; and each of R5a, R6a, R7a and R8a is, independently, hydrogen or lower alkyl. |
| priorityDate | 2008-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451 |
Total number of triples: 29.